Sanegene Bio
PrivateLast Round
Series B
Dec 8, 2025
Total Funding Raised
$266.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Sanegene Bio is a biotechnology company that develops RNA interference (RNAi) therapeutics for obesity, cardiometabolic, and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sanegene Bio Comparables
Compare Sanegene Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Argo Biopharma | 90% | |
| Rona Therapeutics | 85% | |
| Vivatides Therapeutics | 84% |
Sanegene Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 8, 2025 | ||||
| Strategic | Nov 8, 2025 | ||||
| Series A Extension | Dec 1, 2023 | ||||
| Series A | Aug 31, 2021 | ||||
| Series A | Aug 1, 2021 |
Key People
Founding team and executive leadership
Sanegene Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alwin Capital | Series A, Series A Extension |
| SymBiosis Capital Management | Series B |
| Lake Bleu Capital | Series B |
| Shanghai Healthcare Capital | Series A Extension |
| Oriza Holdings | Series A, Series B, Series A Extension |
| Hillhouse Investment | Series B, Series A |
| Tianjin TEDA Science and Technology Investment Co., Ltd. | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 297% MoM, reaching 4.6K.
- Aug 17, 2026
Grew 17% QoQ, from 29 to 34 employees.
Sanegene Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sanegene Bio's valuation, stock price, and market status.
Is Sanegene Bio a public or private company?
Sanegene Bio is a private company.
What is the current stock price of Sanegene Bio?
Sanegene Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Sanegene Bio worth (valuation)?
Valuation information for Sanegene Bio is not publicly available.
Can I buy Sanegene Bio stock?
Sanegene Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sanegene Bio's last funding round?
Sanegene Bio's most recent funding round was Series B on December 8, 2025.
Who are the main investors in Sanegene Bio?
Key investors in Sanegene Bio include Alwin Capital, SymBiosis Capital Management, Lake Bleu Capital, Shanghai Healthcare Capital, Oriza Holdings.
Will Sanegene Bio IPO soon?
No public IPO plans have been announced for Sanegene Bio.
How can I track Sanegene Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sanegene Bio's secondary market activity and sign up for updates.